Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness

Inclusion Criteria: * registration to the French social security system * patients who did not specifically express their non willingness to participate PLUS either A, B or C: 1. Patients with essential hypertension, aged 55 to 75 years old, both sexes * Grade 1 hypertension of more * Treated or not * Whatever the control of BP * Under primary of secondary prevention (more than 3 months stroke or myocard infarctus (MI), or stable angina or peripheral artery disease) PLUS at least 3 CV risk factors according to ESH-ESC 2007 guidelines or metabolic syndrome associating at least 2 of the following criteria * SBP/DBP over 130/85 mmHg * HDL-C \<1.0 mmol/l (0,4 g/l) (M) or \< 1.2 mmol/l (0,46 g/l) (F) * Triglycerides \>1,7 mmol/l (\>1,5 g/l) * Fasting blood glucose 5,6 - 6,9 mmol/l (1,02-1,25 g/l) * Waist circumference \> 102 cm (M) ou 88 cm (F) or Type 2 diabetes or Target organ damage, according to the definition of the ESH-ESC Guidelines for the Management of Hypertension or CV disease or chronic kidney disease 2. SBP \> 180 mmHg and/or DBP \> 110 mmHg 3. SBP \> 160 mmHg AND DBP \< 70 mmHg Exclusion Criteria: * Patients with ABPM or self-measurement normal without treatment (\<130 mmHg and 80 in the ABPM 24 or \<135 and 85 mmHg or daytime ABPM self-measurement of blood pressure) * Patients with secondary hypertension (renal artery stenosis, pheochromocytoma, or hypermineralocortisism) * Patients with hypertension secondary to diabetic nephropathy * Patients aged under 55 or over 75 years, * Low-risk CV patients * Patients with severe chronic renal impairment creatinine clearance (MDRD) \<30ml / min / 1.73m2 * Patients with type I diabetes * Patients with severe disease threatening the vital prognosis in the short and medium terms * Patients who previously experienced a painful gynecomastia under spironolactone * Patients with alcohol dependence or excessive consumption alcoholic beverages (at the judgement of the investigator) * patients with accident history neurovascular, coronary insufficiency (coronary bypass surgery or percutaneous coronary intervention) not older than 3 month * Patients with a history of acute heart failure or having open failure heart (NYHA class III-IV) * Patients with unstable angina * Auricular Fibrillation (AF) less than 6 months ago * Patients with aortic stent * Patients with known aneurysms of the abdominal aorta * Patients with atrioventricular block second or third degree without pacemaker * Patients having received organ transplant or placed on a waiting list for transplantation * Patients with severe chronic inflammatory disease (rheumatoid arthritis; lupus; scleroderma ...) * Patients with severe chronic infectious disease * Patients who have had an MI less than 3 months ago * Patients with stroke there are less than 3 months ago * Patients with progression of peripheral arterial disease * Patient whose pregnancy is known or which has no effective contraception if is of childbearing age, or if she is breastfeeding * Patients who have expressed their opposition to participate in the protocol or have an inability to understand or follow the protocol * The patients geographically too far from the place of investigation * Patients already participating in other drug research protocol or Interventional